[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "US pause Janssen vaccine", "description": "Joint CDC and FDA Statement on Johnson & Johnson COVID-19 Vaccine\n\nhttps://www.cdc.gov/media/releases/2021/s0413-JJ-vaccine.html\n\nhttps://www.washingtonpost.com/health/2021/04/13/johnson-and-johnson-vaccine-blood-clots/\n\nCerebral venous sinus thrombosis, together with low platelets\n\nSome sort of immune response\n\n6 cases from 6.8 million doses\n\nLook out for, severe headache, abdominal pain, leg pain or shortness of breath within three weeks of vaccination\n\nPaul A.Offit, vaccine specialist, Children\u2019s Hospital of Philadelphia\n\nI think it\u2019s the prudent thing to do \n\nI think it\u2019s real \u2014 this is a rare, but real association\n\nAdvisory Committee on Immunization Practices (ACIP), meets today\n\nEMA also investigating, delaying European rollout\n\nJanet Woodcock, acting commissioner, Food and Drug Administration\n\nOne reason for the pause, health professionals must know not to use heparin\n\nAll six cases in the US, occurred among women, 18 to 48\n\n6 \u2013 13 days after vaccination\n\nOf the 6, 1 death and 1 critical\n\nOf the 6, 2 discharged\n\nThe person in critical condition was (reportedly) treated with heparin\n\nPeter Marks, director of the FDA's centre for biologics evaluation and research\n\nhesitate to call it a class effect related to adenovirus vector vaccines\n\nIt's plainly obvious to us already that what we're seeing with the Jansen vaccines looks very similar to what is being seen with the AstraZeneca vaccine\n\nAstraZeneca, chimpanzee adenoviral vector \n\nJanssen, human adenoviral vector vaccine\n\nI can't make some broad statement yet, but obviously they are from the same general class of viral vectors\n\nScale of the problem\n\n100 million doses to US end of May\n\ncan produce 1 billion doses globally by the end of the year\n\nhas agreed to sell 500 million doses to developing nations via Covax purchasing agreement\n\nagreed to sell up to 400 million to African countries\n\nTurkey\n\nhttps://www.telegraph.co.uk/global-health/science-and-disease/coronavirus-news-lockdown-pubs-restaurants-shops-cases-deaths/\n\nCases, + 59,187 = 3,962,000 million\n\n Deaths, + 273 = 34,455\n\nPresident Tayyip Erdogan, partial closures\n\nRamadan started yesterday\n\nFrance\n\nCases, + 39,113 = 5,100,000\n\nDeaths, + 324 (in hospital) = 99,480\n\nITU = 5,952\n\nOne month lockdown in place since the end of March\n\nFrance will suspend all flights to and from Brazil\n\nSweden\n\nAZ, being given to over 65s\n\nJ&J arriving this week\n\nRussia\n\nManufacturing of Sputnik V, soon in India, (50 m per month) Serbia, Iran, Italy\n\nIndia\n\nIndia approved Sputnik V on Monday\n\nUK\n\nhttps://www.telegraph.co.uk/global-health/science-and-disease/lockdown-eases-worried-should-londons-cluster-south-african/\n\nSurge PCR testing south London\n\nLambeth and Wandsworth (population 656,000)\n\nTesting available for all, symptomatic or asymptomatic\n\nLive, work or travel through\n\nSouth Africa variant\n\nEeek, E484K, seems to reduce AZ efficacy\n\nStill protects against severe disease\n\nDoes not seem to out compete UK variant\n\nNew formulation of AZ for third shot later this year\n\nWho are these guys?\n\nVitamin D\n\nhttps://vdmeta.com", "link": "https://www.youtube.com/watch?v=GIfzd_lJDhU", "date_published": "2021-04-14 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Therapeutics update", "description": "WHO latest COVAX news release\n\nhttps://www.who.int/news/item/08-04-2021-covax-reaches-over-100-economies-42-days-after-first-international-delivery\n\nFirst international delivery, Ghana, 24 February 2021\n\nNow delivered vaccines to over 100 economies\n\nSo far, 38 million doses of vaccines\n\nAstraZeneca, Pfizer-BioNTech and Serum Institute of India\n\nDelays in planned deliveries for March and April\n\nAs of 13th April\n\nhttps://www.bloomberg.com/graphics/covid-vaccine-tracker-global-distribution/\n\n797 doses given in 154 countries\n\nNow, 18 million per day\n\nFor a further 7 billion people, needing 2 doses\n\nOver two years\n\nWHO, Solidarity trials\n\n12 000 patients in 500 hospital sites in over 30 countries\n\nhttps://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments\n\nfound that all 4 treatments evaluated \n\nremdesivir, hydroxychloroquine, lopinavir/ritonavir and interferon\n\nhad little or no effect on overall\n\nmortality\n\ninitiation of ventilation\n\nduration of hospital stay in hospitalized patients\n\nThe Solidarity Trial is considering evaluating other treatments, to continue the search for effective COVID-19 therapeutics\n\nSo far, only corticosteroids have been proven effective against severe and critical COVID-19.\nWHO advises that ivermectin only be used to treat COVID-19 within clinical trials\n\nhttps://www.who.int/news-room/feature-stories/detail/who-advises-that-ivermectin-only-be-used-to-treat-covid-19-within-clinical-trials\n\nhttps://www.forbes.com/sites/jvchamary/2021/01/31/remdesivir-covid-coronavirus/?sh=6a517c1c66c2\n\nUK bases Recovery trial\n\nhttps://www.recoverytrial.net\n\nhttps://www.bmj.com/content/370/bmj.m2670\n\nAzithromycin\n\nhttps://www.recoverytrial.net/results/azithromycin-results\n\nRECOVERY trial finds no benefit from azithromycin in patients hospitalised with COVID-19 \n\nConvalescent Plasma\n\nhttps://www.recoverytrial.net/results/convalescent-plasma\n\nData Monitoring Committee saw no convincing evidence that further recruitment would provide conclusive proof of worthwhile mortality benefit \n\nDexamethasone\n\nhttps://www.recoverytrial.net/files/recovery_dexamethasone_statement_160620_v2final.pdf\n\nDexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19 \n\nHydroxychloroquine\n\nhttps://www.recoverytrial.net/files/hcq-recovery-statement-050620-final-002.pdf\n\nNo clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19 \n\nLopinavir-ritonavir\n\nhttps://www.recoverytrial.net/results/lopinavar-results\n\nNo clinical benefit from use of lopinavir-ritonavir in hospitalised COVID-19 patients\n\nTocilizumab\n\nhttps://www.recoverytrial.net/results/tocilizumab-results\n\nTocilizumab reduces deaths when given to hospitalised patients with severe COVID-19\n\nShortens time until patients are successfully discharged from hospital\n\nReduces the need for a mechanical ventilator\n\nPharmacy Magazine, ivermectin article\n\nhttps://www.pharmacymagazine.co.uk/ivermectin-for-covid-19-a-cheap-drug-with-a-remarkable-effect\n\nIntroduced in 1981\n\nAntiviral and anti-inflammatory properties\n\nSome 4 billion doses have been taken over the past 40 years\n\nGood safety record with minimal toxic effects\n\nWHO Model List of Essential Medicines as a 3mg tablet\n\nCountries now including ivermectin in their Covid-19 management strategies\n\nGreece, Bulgaria, Macedonia, Slovakia, Czech Republic\n\nFront Line Covid-19 Critical Care (FLCCC) Alliance\n\nCalled for the rapid introduction of ivermectin to stem the tide of infections\n\nProphylactic treatment can be given with two doses of 0.2mg/kg, 48 hours apart, once a month. \n\nFor early out-patient treatment, a daily dose of 0.2mg/kg for a maximum of five days is recommended\n\nIn the UK, the best way forward would be for the MHRA to authorise use of ivermectin for prophylaxis and treatment of Covid-19 on the basis of the published evidence to date. \n\nNext, the drug could be made available through community pharmacies either using a PGD or by making ivermectin a P medicine\n\nIvermectin would then help to save lives and reduce suffering until the majority of the population can be vaccinated\n\nFailure to use a cheap, safe drug that reduces the severity and duration of infection as well as the risks of death and transmission seems incomprehensible\n\nFacebook, Partly false information\n\nhttps://healthfeedback.org/claimreview/ivermectin-isnt-a-highly-effective-drug-for-treating-covid-19-tess-lawrie/?fbclid=IwAR1f1uy6y2bF8juhMuhZFjM86GhYq7ou-cHgxBP4VmrBGc6jtPLmGhxzQiU\n\nCurrent NICE guidelines\n\nhttps://www.nice.org.uk/guidance/ng191/resources/covid19-rapid-guideline-managing-covid19-pdf-66142077109189", "link": "https://www.youtube.com/watch?v=ATmL_2Jqh-I", "date_published": "2021-04-13 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]